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Abstract
Objective The aim of the present paper was to review the
literature in order to summarize the effects of marine n-3
fatty acids on circulating inﬂammatory markers among
healthy subjects, subjects with high risk of developing
cardiovascular disease (CVD) and in patients with CVD in
human intervention studies.
Methods A systematic literature search in PubMed was
performed. Intervention studies describing the effects of
marine n-3 fatty acids on circulating inﬂammatory markers
in healthy subjects, subjects with high risk of CVD and
patients with CVD were included. The following exclusion
criteria were used: (1) interventions assessing inﬂammatory
markers with ex vivo methods (2) interventions with chil-
dren (3) articles describing animal or cell culture studies.
Twenty-two articles were included. Additionally, 13 papers
from their literature lists were included based on the same
inclusion and exclusion criteria as the literature search.
Results and conclusion Intervention studies with marine
n-3 fatty acids administered from either ﬁsh or ﬁsh oil
demonstrate different results on inﬂammatory markers. No
ﬁrm conclusion can be drawn about the effect of marine
n-3 fatty acids on circulating inﬂammatory markers in
healthy individuals, individuals with high risk of devel-
oping CVD or individuals with CVD related diseases.
Keywords Omega-3 fatty acids   Atherosclerosis  
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Introduction
Fish consumption reduces the risk of developing cardio-
vascular disease (CVD) and CVD mortality [1, 2]. Reduced
total mortality and major coronary events, including fatal
and non-fatal MI, are observed in intervention trials after
intake of ﬁsh and ﬁsh oil containing the marine n-3 fatty
acids eicosapentaenoic acid (EPA, 20:5 n-3) and docosa-
hexaenoic acid (DHA, 22:6 n-3) [3–6]. The association
between high intakes of marine n-3 fatty acids and
decreased morbidity and mortality from CVD can be
explained by the decrease in plasma triglycerides [7, 8],
moderate reduction in blood pressure [9] and reduced
blood plate aggregation [10, 11]. Protection against cardiac
arrhythmias has also been shown but the effect is still under
discussion [12, 13].
Atherosclerosis is the underlying cause of most CVD. In
atherosclerosis, the combined action of risk factors causes
the gradual thickening of the arterial wall due to lipid
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123accumulation to form an atherosclerotic plaque which can
abruptly rupture, causing thrombosis. Inﬂammation has
emerged as a major player in the development and pro-
gression of atherosclerosis [14]. There is an association
between various biomarkers of inﬂammation and pro-
spective CVD risk in apparently healthy individuals as well
as in patients with CVD or heart failure. Systemic bio-
markers of early and late atherosclerosis are of great
clinical interest due to their potential for identifying high
risk patients. Even though there are some good candidates,
only C-reactive protein (CRP) has emerged as a leading
biomarker of inﬂammation for clinical application [15, 16];
other markers with appropriate robustness, sensitivity and
speciﬁcity have not yet emerged. Based on the fact that
endothelial dysfunction is the earliest manifestation of
atherosclerosis, along with the involvement of oxidative
stress and inﬂammation at all stages of coronary athero-
sclerosis development, biomarkers such as soluble
intracellular adhesion molecule (sICAM-1) and soluble
vascular adhesion molecule (sVCAM-1), soluble E-selectin
(sE-sel) (for endothelial activation), interleukin (IL)-6
(transcriptional driver of CRP) and monocyte chemoat-
tractant protein (MCP)-1 (produced by activated
vasculature) are of particular interest (Table 1). So far
CRP, IL-6, sVCAM-1 and sICAM-1 provide prognostic
information beyond that obtained by clinical variables after
acute coronary syndromes; these mediators seem to be
powerful predictors of subsequent cardiovascular events.
[17, 18]. Recently, intake of marine n-3 fatty acids has
been associated with reduced plasma levels of inﬂamma-
tory markers [19–21].
The aim of the present paper was to review the literature
in order to summarize the effects of marine n-3 fatty acids
on circulating inﬂammatory markers among healthy sub-
jects, subjects with high risk of developing CVD and in
patients with CVD in human intervention studies.
Methods of this review
The systematic literature search was conducted in PubMed
in 2009 using the following terms: ‘‘eicosapentaenoic acid
OR docosapentaenoic acid OR docosahexaenoic acid OR
omega-3 OR ﬁsh oil OR cod liver oil AND inﬂammation’’.
The following limitations were included in the search:
‘‘added to PubMed in the last 10 years, published in the
last 10 years, Humans, Clinical Trial, English’’. In total,
91 articles were identiﬁed. Based on these papers, we
included all studies that measured the effect of marine n-3
fatty acids on circulating inﬂammatory markers in plasma
or serum among apparently healthy individuals (Table 2),
individuals with high risk of developing CVD (Table 3)o r
individuals with CVD (Table 4). Interventions with marine
n-3 fatty acids given as supplements or in the diet as ﬁsh
were included. The following exclusion criteria were used:
(1) interventions assessing inﬂammatory markers with ex
Table 1 Relevant inﬂammatory markers and their biological function
Inﬂammatory markers Abbreviation Function
Acute-phase protein
C-reactive protein CRP CRP is associated with the formation of cytokines, chemokines
and the acute-phase response
Cytokines
Interleukin-6 IL-6 Induces acute-phase response (by inducing CRP), anti-body
secretion and differentiation
Interleukin-1a, Interleukin-1b IL-1a, IL-1b Proliferation and maturation of lymphocytes, involved in
inﬂammation and acute-phase response
Interleukin-18 IL-18 Involved in the formation of Th1 cells
Tumor necrosis factor-a is a cytokine TNF-a Induces adhesion molecules- and cytokine expression,
involved in cell death
Adhesion protein
Soluble intercellular adhesion molecule-1 sICAM-1 Binds monocytes and lymphocytes to the endothelium
Soluble vascular cell adhesion molecule-1 sVCAM-1 Binds monocytes and lymphocytes to the endothelium
sE-selectin sE-sel Recruits leukocytes to the inﬂammatory site
sP-selectin sP-sel Recruits leukocytes to the inﬂammatory site. Induces
monocytes and platelet interactions
Chemokines
Monocyte chemoattractant protein-1 MCP-1 Facilitates migration of leukocytes to the intima
Granulocyte–macrophage colony-stimulating factor GM–CSF Growth and differentiation of monocytes
Interleukin-8 IL-8 Facilitates migration of leukocytes to the intima
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123vivo methods (2), interventions with children (3) and
articles describing animal or cell culture studies. After
reading abstracts of the 91 papers, 22 articles were inclu-
ded. The literature lists of the selected papers were checked
and 13 additional relevant papers were included based on
the same inclusion and exclusion criteria as the literature
search. The search was re-run in August 2010. However,
no further papers were included from this search.
Results
Details of the 35 studies selected in this review are given in
Tables 2, 3 and 4. Twenty-nine of these are based on
marine n-3 fatty acids given as supplements, whereas six
studies are dietary interventions with ﬁsh. Both categories
of interventions are given in the tables.
The systematic review of the literature reveals that
seven out of thirteen trials reported an effect on circulating
inﬂammatory markers [22–34] in healthy individ-
uals (Table 2). Six of the studies did not observe any
changes in inﬂammatory markers [22–24, 26, 29, 33]
(Table 2). C-reactive protein (CRP) was analyzed in seven
of the trials, and in ﬁve of these no effect in CRP levels was
observed [22–26], while a reduction in plasma concentra-
tion of CRP after intake of marine n-3 fatty acids was
reported in two of the trials [27, 28]. Five of the thirteen
trials analyzed the plasma concentration of IL-6. Two of
these reported a reduction in IL-6 levels [27, 28], whereas
three did not demonstrate any effect on IL-6 levels [25, 29,
33]. Table 2 also reveals that marine n-3 fatty acids
reduced or had no effects on the concentration of sICAM-1
in ﬁve of the trials [25, 29, 31, 32, 34]. The concentration
of sVCAM-1 was reduced, increased or unchanged after
intake of marine n-3 fatty acids among healthy individuals
in these trials, whereas the level of sE-sel increased or
remained unchanged [25, 31, 32, 34]. The effects of marine
n-3 fatty acids on circulating inﬂammatory markers among
individuals with a high risk of developing CVD are shown
in Table 3 [35–49]. Four of ﬁfteen trials reported a
reduction in the concentration of inﬂammatory markers
after intake of marine n-3 fatty acids [35, 36, 45, 46], while
nine studies did not observe any effects on inﬂammation
[37–44, 48]. An increase in inﬂammatory markers [49] was
reported in one study. One of nine studies where CRP was
analyzed demonstrated a reduction in the concentration of
CRP after intake of marine n-3 fatty acids [36]. Three trials
demonstrated a reduction in plasma cytokines or soluble
adhesion molecules [35, 45, 46]. Table 4 reviews the
effects of marine n-3 fatty acids on circulating inﬂamma-
tory markers among individuals with CVD or CVD related
diseases [50–56]. Five of seven studies showed no change
in the concentration of inﬂammatory markers after intake
of marine n-3 fatty acids [50–53, 55], whereas one study
reported a reduction in the levels of IL-6 and sVCAM-1
[54] and one trial showed an increase in the level of sE-sel
and sVCAM -1 [56].
Discussion and conclusion
Effect of marine n-3 fatty acids on circulating
inﬂammatory markers
Intervention trials with marine n-3 fatty acids administered
either from ﬁsh or ﬁsh oil supplements demonstrate dif-
ferent results on circulating inﬂammatory markers in
healthy individuals, individuals with high risk of devel-
oping CVD or individuals with CVD related diseases.
Based on these ﬁndings, a ﬁrm conclusion about the effect
of marine n-3 fatty acids on circulating inﬂammatory
markers cannot be drawn. The majority of the trials do not
show any effect, however a decreased level of circulating
CRP and IL-6 are observed in some studies, whereas the
circulating level of adhesion molecules inconsistently are
elevated, decreased or not changed. The reasons for the
different results may be several. First of all, a local
inﬂammatory improvement in the arterial wall will not
necessary be reﬂected in the circulation and may explain
the lack of effect observed after intake of marine n-3 fatty
acids. Several of the reported trials have a relative small
number of study subjects and probably low statistical
power. Variation in the results can also be explained by
differences in the administration of the marine n-3 fatty
acids (supplement vs. diet) as well as the doses used.
Furthermore, there is uncertainty regarding the background
diet and to what extend the intervention changed the bal-
ance between n-3 and n-6 fatty acids or altered the intake
of saturated fat in the diet.
Comparing the results on the effects of marine n-3 fatty
acids given as supplements on serum CRP in healthy
individuals, the baseline level of CRP seems crucial.
Ciubotaru et al. [27] reported a signiﬁcant reduction in the
level of CRP in postmenopausal women who had mean
baseline levels of CRP above 6 mg/L. This is in contrast to
the results from Geelen et al. [22], Vega-Lopez et al. [23]
and Madsen et al. [24] who did not observe any changes in
the CRP serum levels. The baseline level of serum CRP in
the subjects in these studies was approximately 1 mg/L.
Vega-Lopez et al. [23] failed to see any effect on the serum
CRP level using a daily dose of 0.6 g EPA and 0.9 DHA
for 12 weeks, which is in line with the results from Madsen
et al. [24] who used two different daily doses (3.0 g
EPA ? 2.9 g DHA or 0.9 g EPA ? 0.8 g DHA). In con-
trast, Ciubotaru et al. [27] observed in postmenopausal
women that the effect on CRP is dependent on the dose of
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123marine n-3 fatty acids. A larger decrease in CRP was
observed in the women who received the highest dose of
marine n-3 fatty acids (2.56 g/d) compared to those
receiving a daily dose of 1.3 g marine n-3 fatty acids.
It is interesting to note that observed decrease in cir-
culating CRP level was associated with decrease in
circulating IL-6 level after intake of marine n-3 fatty acids,
both via supplement or diet. In this review there are rela-
tively few studies where marine n-3 fatty acids are
administered as ﬁsh. When comparing these interventions
with the interventions with ﬁsh oil, there are indications for
a more prominent effect on circulating inﬂammatory
markers with ﬁsh containing diet. Reductions or no change
in one of the following markers (CRP, IL-6, sICAM-1,
sVCAM-1, IL-18, sE-sel) are observed in all the six dietary
studies included in this review. A possible explanation
could be that subjects participating in dietary intervention
trials may change their overall dietary pattern resulting in
more awareness of healthy lifestyle, which again may
inﬂuence the circulating inﬂammatory markers. Fish may
also contain other bioactive compounds that may inﬂuence
outcome.
New strategies for studying effects of marine n-3 fatty
acids on inﬂammation
To further understand if marine n-3 fatty acids have an
effect on inﬂammation in relation to atherosclerosis and the
underlying molecular mechanisms responsible for their
inﬂammatory response, new strategies should be consid-
ered. When inﬂammatory markers are measured in the
circulation, the local effect in monocytes will not necessary
be detected since the monocytes only contribute to about
5% of the total cells in plasma. The peripheral blood
mononuclear cells (PBMCs) include monocytes and lym-
phocytes, which are cells central in inﬂammation and
hence in the atherosclerosis process. The PBMCs are
exposed to many of the same environmental factors as the
arterial wall. Alterations in gene expression levels in these
cells can thus be demonstrated early in the process before
signs of inﬂammation can be seen in vivo, and thus con-
stitute an important source of biomarkers for progression of
atherosclerotic disease. PBMCs are easily available, which
makes them suitable for studying gene expression of
mediators involved in the early development of athero-
sclerosis [57]. A previous study recently demonstrated that
166 genes among 182 candidate cardiovascular genes were
expressed in PBMCs [58].
The ability of marine n-3 fatty acids to alter gene
expression has been clearly demonstrated in vitro and may
account for its potential beneﬁcial health effects. Fatty
acids regulate expression of genes involved in lipid
metabolism and inﬂammation by acting as ligands for the
peroxisomal proliferator-activated receptors (PPARs) [59].
Fatty acids are also known to reduce the activation of the
transcription factor nuclear factor kappa B (NF-jB) prob-
ably by interference with the PPARs [60, 61] or the Toll-
like receptors [62, 63]. The G protein-coupled receptor 120
(GPR120) has recently been characterized as an n-3 fatty
acid receptor/sensor involved in the anti-inﬂammatory
effects of n-3 fatty acids [64]. PPAR and PPAR target
genes are expressed in PBMCs [65]. Dietary supplements
containing ﬁsh oil have also been shown to affect expres-
sion of PI3K, Akt, NF-jB and inﬂammatory cytokines in
mononuclear cells [66].
To obtain a more comprehensive overview of the pro-
cesses that are modulated by EPA and DHA, new ‘‘omics’’
technologies can be used to detect large scale changes in
gene expression proﬁles (transcriptomics). Whole genome
transcriptomic analysis in PBMCs will be valuable in fur-
ther understanding the inﬂammatory role of n-3 fatty acids
in humans. Recently, a human intervention study among
elderly who daily consumed ﬁsh oil (containing 1.8 g EPA
and DHA) for 26 weeks demonstrated changes in the gene
expression proﬁles in PBMCs. Gene transcripts involved in
inﬂammation and other processes of atherosclerosis were
down-regulated among those who had consumed ﬁsh oil
[67]. The combined use of other ‘‘omics’’ technologies,
such as proteomics and metabolomics (lipidomics), in
intervention studies will further extend the understanding
of the effects of marine n-3 fatty acids on inﬂammation.
Using proteomics technology, a recent study demonstrated
that daily intake of 3.5 g ﬁsh oil down-regulated a number
of proteins involved in the acute phase response and lipid/
lipoprotein metabolism [68]. Furthermore, Lankinen et al.
[69] previously used a lipidomics approach in an inter-
vention study where 33 individuals randomized to eat fatty
ﬁsh (150 g four times per week), lean ﬁsh (150 g four
times per week) or no ﬁsh, in 8 weeks. They observed a
reduction in the level of lipid metabolites related to
inﬂammation and insulin-signaling among those eating
fatty ﬁsh.
No ﬁrm conclusion about the effect of marine n-3 fatty
acids on circulating inﬂammatory markers can be drawn in
this review. A systematic use of transcriptome, proteome,
and metabolome technologies for the construction of net-
work based models of biological processes has emerged as
an exciting research approach in molecular biology and
functional genomics. In future marine n-3 supplementation
and dietary intervention trials, systems biology combined
with traditional circulating markers may help us to gain
more insight into the underlying molecular mechanisms of
marine n-3 fatty acids responsible for the inﬂammatory
response in the progression of atherosclerotic disease.
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